Dublin-based infectious disease specialist Poolbeg Pharma has received a green light from Japan’s patent office, relating to a patent application for the company’s “potential blockbuster treatment” for severe influenza.
The Japanese Patent Office has issued a notice of allowance for Poolbeg’s Immunomodulator I patent application, and it is expected that a granting of the application will follow upon completion of formalities.
The Japanese notice of allowance relates to a class of p38 MAPK (mitogen-activated protein kinase) inhibitors to treat influenza, which includes Poolbeg’s POLB 001 treatment.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
